| Citation: |
WANG Qi, CHEN Miao. Advances in Immunotargeted Therapy for Warm Autoimmune Hemolytic Anemia[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(2): 423-430. DOI: 10.12290/xhyxzz.2024-0668
|
Warm autoimmune hemolytic anemia (wAIHA) is an autoimmune disorder mediated by autoantibodies. With an increasing understanding of the immunopathogenesis of wAIHA, significant progress has been made in the development of drugs targeting different components of the immune system. Consequently, these emerging drugs provide more options for the treatment of patients with wAIHA. Anti-B-cell targeted therapies, represented by novel CD20 monoclonal antibodies, Bruton tyrosine kinase (BTK) inhibitors, phosphatidylinositol 3-kinases(PI3K) inhibitors, and B-cell activating factor of the TNF family (BAFF) inhibitors, have shown remarkable efficacy. Additionally, anti-plasma cell targeted therapies, exemplified by proteasome inhibitors and CD38 monoclonal antibodies, have also demonstrated significant outcomes. Furthermore, advances have been achieved in complement inhibitors, neonatal Fc receptor (FcRn) monoclonal antibodies, spleen tyrosine kinase (SYK) inhibitors, and mammalian target of rapamycin (mTOR) inhibitors. This article reviews the recent advances in immunotargeted therapy for wAIHA, aiming to provide a reference for clinical practice.
| [1] |
Eaton W W, Rose N R, Kalaydjian A, et al. Epidemiology of autoimmune diseases in Denmark[J]. J Autoimmun, 2007, 29(1): 1-9. DOI: 10.1016/j.jaut.2007.05.002
|
| [2] |
Packman C H. Hemolytic anemia due to warm autoantibodies[J]. Blood Rev, 2008, 22(1): 17-31. DOI: 10.1016/j.blre.2007.08.001
|
| [3] |
Berentsen S, Barcellini W. Autoimmune hemolytic anemias[J]. N Engl J Med, 2021, 385(15): 1407-1419. DOI: 10.1056/NEJMra2033982
|
| [4] |
Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells[J]. Semin Hematol, 2010, 47(2): 170-179. DOI: 10.1053/j.seminhematol.2010.01.010
|
| [5] |
Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies[J]. Autoimmun Rev, 2015, 14(4): 304-313. DOI: 10.1016/j.autrev.2014.11.014
|
| [6] |
Birgens H, Frederiksen H, Hasselbalch H C, et al. A phase Ⅲ randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia[J]. Br J Haematol, 2013, 163(3): 393-399. DOI: 10.1111/bjh.12541
|
| [7] |
Michel M, Terriou L, Roudot-Thoraval F, et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)[J]. Am J Hematol, 2017, 92(1): 23-27. DOI: 10.1002/ajh.24570
|
| [8] |
Coiffier B, Lepretre S, Pedersen L M, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study[J]. Blood, 2008, 111(3): 1094-1100. DOI: 10.1182/blood-2007-09-111781
|
| [9] |
Poulet A, Jarrot P A, Mazodier K, et al. Successful treatment of systemic lupus erythematosus-related refractory autoimmune hemolytic anemia with ofatumumab[J]. Lupus, 2019, 28(14): 1735-1736. DOI: 10.1177/0961203319881500
|
| [10] |
Herishanu Y, Levi S, Kamdjou T, et al. Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lympho-cytic leukaemia/small lymphocytic lymphoma[J]. Br J Haematol, 2021, 192(1): e1-e4. DOI: 10.1111/bjh.16821
|
| [11] |
方力维, 潘虹, 施均. 伊布替尼治疗复发/难治原发性自身免疫性溶血性贫血二例——探索性研究[J]. 中华血液学杂志, 2020, 41(5): 412-416.
Fang L W, Pan H, Shi J. Ibrutinib treatment for 2 cases of relapsed/refractory autoimmune hemolytic anemia: a pilot study[J]. Chin J Hematol, 2020, 41(5): 412-416.
|
| [12] |
朱兆轩, 王琦, 庄俊玲, 等. 第503例——单克隆IgM血症、重度贫血、反复发热[J]. 中华内科杂志, 2023, 62(11): 1369-1372. DOI: 10.3760/cma.j.cn112138-20230302-00127
Zhu Z X, Wang Q, Zhuang J L, et al. The 503rd case: monoclonal IgM immunoglobulinemia, severe anemia with recurrent fever[J]. Chin J Intern Med, 2023, 62(11): 1369-1372. DOI: 10.3760/cma.j.cn112138-20230302-00127
|
| [13] |
Nikitin E, Kislova M, Morozov D, et al. Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias[J]. Leukemia, 2023, 37(7): 1464-1473. DOI: 10.1038/s41375-023-01891-3
|
| [14] |
Institute of Hematology & Blood Diseases Hospital, China. The safety and efficacy of Ibrutinib in refractory/relapsed autoimmune hemolytic anemia. (2024-09-25)[2024-10-20]. https://clinicaltrials.gov/study/NCT04398459.
|
| [15] |
Rogers K A, Lehman A M, Cheney C, et al. Inhibitors of Bruton's tyrosine kinase reduce anti-red blood cell response in a murine model of autoimmune hemolytic anemia[J]. Blood, 2016, 128(22): 1259. DOI: 10.1182/blood.V128.22.1259.1259
|
| [16] |
Byrd J C, Wierda W G, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results[J]. Blood, 2020, 135(15): 1204-1213. DOI: 10.1182/blood.2018884940
|
| [17] |
Sanofi. Efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia (wAIHA)[J]. (2025-02-28)[2025-03-12]. https://clinicaltrials.gov/study/NCT05002777.
|
| [18] |
Puri K D, Gold M R. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies[J]. Front Immunol, 2012, 3: 256.
|
| [19] |
Quinquenel A, Godet S, Dartigeas C, et al. Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group[J]. Am J Hematol, 2019, 94(7): E183-E185.
|
| [20] |
Scuron M D, Fay B L, Connell A J, et al. The PI3Kδ inhibitor parsaclisib ameliorates pathology and reduces autoanti-body formation in preclinical models of systemic lupus erythematosus and Sjögren's syndrome[J]. Int Immunopharmacol, 2021, 98: 107904. DOI: 10.1016/j.intimp.2021.107904
|
| [21] |
Barcellini W, Murakhovskaya I, Terriou L, et al. Long-term efficacy and safety results from an ongoing open-label phase 2 study of parsaclisib for the treatment of autoimmune hemolytic anemia[C] //European Hematology Association (EHA) 2022 Hybrid Congress. Vienna: European Hematology Association, 2022: 1-13.
|
| [22] |
Xu Z Z, Zhao B B, Xiong H, et al. Serum BAFF and April levels in patients with autoimmune hemolytic anemia and their clinical significance[J]. Int J Hematol, 2015, 102(4): 394-400. DOI: 10.1007/s12185-015-1851-8
|
| [23] |
Novartis Pharmaceuticals. A study of efficacy and safety of ianalumab in previously treated patients with warm autoimmune hemolytic anemia (VAYHIA)[EB/OL ]. (2024- 08-22)[2024-12-20]. https://clinicaltrials.gov/study/NCT05757570.
|
| [24] |
Alpine Immune Sciences, Inc. An open-label study of povetacicept in subjects with autoimmune cytopenias (RUBY-4)[ EB/OL ]. (2023-03-07)[2023-07-05]. https://classic.clinicaltrials.gov/ct2/show/NCT05757570.
|
| [25] |
Zenas BioPharma (USA), LLC. A study of obexelimab in patients with warm autoimmune hemolytic anemia (SApHiAre)[EB/OL ]. (2025-02-03)[2025-02-28]. https://clinicaltrials.gov/study/NCT05786573.
|
| [26] |
Ratnasingam S, Walker P A, Tran H, et al. Bortezomib-based antibody depletion for refractory autoimmune hematological diseases[J]. Blood Adv, 2016, 1(1): 31-35. DOI: 10.1182/bloodadvances.2016001412
|
| [27] |
Chen M, Zhuang J L, Yang C, et al. Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia[J]. Ann Hematol, 2020, 99(5): 1141-1143. DOI: 10.1007/s00277-020-03976-w
|
| [28] |
Yao M K, Zhang J J, Li Y, et al. Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia[J]. Medicine (Baltimore), 2022, 101(4): e28679. DOI: 10.1097/MD.0000000000028679
|
| [29] |
Benfaremo D, Gabrielli A. Is there a future for anti-CD38 antibody therapy in systemic autoimmune diseases?[J]. Cells, 2019, 9(1): 77. DOI: 10.3390/cells9010077
|
| [30] |
Even-Or E, Naser Eddin A, Shadur B, et al. Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia[J]. Pediatr Blood Cancer, 2020, 67(1): e28010. DOI: 10.1002/pbc.28010
|
| [31] |
Rieger M J, Stolz S M, Ludwig S, et al. Daratumumab in rituximab-refractory autoimmune haemolytic anaemia[J]. Br J Haematol, 2021, 194(5): 931-934. DOI: 10.1111/bjh.17655
|
| [32] |
McGlothlin J, Abeykoon J, Al-Hattab E, et al. Bortezomib and daratumumab in refractory autoimmune hemolytic anemia[J]. Am J Hematol, 2023, 98(10): E263-E265.
|
| [33] |
Dartmouth Health. The safety of repurposing daratumumab for relapsed or refractory autoimmune antibody mediated hemolytic anemia (DARA-AIHA)[EB/OL ]. (2022-03-21)[2023-07-05]. https://ctv.veeva.com/study/the-safety-of-repurposing-daratumumab-for-relapsed-or-refractory-autoimmune-antibody-mediated-hemoly.
|
| [34] |
Sanofi. Safety, pharmacokinetics, and efficacy of subcutaneous isatuximab in adults with warm autoimmune hemolytic anemia(wAIHA)[EB/OL ]. (2024-12-05)[2025-01-20]. https://clinicaltrials.gov/study/NCT04661033.
|
| [35] |
Wang Z, Bo L J, Xu Y, et al. Features of serum complement C3 and C4 levels in autoimmune hemolytic anemia patients[J]. Int J Lab Hematol, 2021, 43(5): 1154-1158. DOI: 10.1111/ijlh.13469
|
| [36] |
Ma K, Caplan S. Refractory IgG warm autoimmune hemolytic anemia treated with eculizumab: a novel applica-tion of anticomplement therapy[J]. Case Rep Hematol, 2016, 2016: 9181698.
|
| [37] |
Gauchy A C, Hentzien M, Wynckel A, et al. Efficacy of eculizumab in refractory life-threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia[J]. Clin Case Rep, 2020, 8(12): 2641-2644. DOI: 10.1002/ccr3.3250
|
| [38] |
Jackson E M, Harper S, Webb G J, et al. Severe refractory warm autoimmune haemolytic anaemia after the SARS-CoV-2 Pfizer-BioNTech vaccine (BNT162b2 mRNA) managed with emergency splenectomy and complement inhibition with eculizumab[J]. BMJ Case Rep, 2022, 15(8): e250774. DOI: 10.1136/bcr-2022-250774
|
| [39] |
Neave L, Wilson A J, Lissack M, et al. Severe refractory idiopathic warm autoimmune haemolytic anaemia responsive to complement inhibition with eculizumab[J]. BMJ Case Rep, 2018, 11(1): e226429. DOI: 10.1136/bcr-2018-226429
|
| [40] |
Garg M, Agarwal S, Altohami M. A single dose of eculizumab terminated life-threatening haemolysis in idiopathic IgM-mediated warm autoimmune haemolytic anaemia: a case report[J]. Br J Haematol, 2022, 197(2): e28-e31.
|
| [41] |
Chao M P, Hong J, Kunder C, et al. Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab[J]. Am J Hematol, 2015, 90(1): 78-81. DOI: 10.1002/ajh.23791
|
| [42] |
Grossi F, Shum M K, Gertz M A, et al. Inhibition of C3 with APL-2 results in normalisation of markers of intravascular and extravascular hemolysis in patients with autoimmune hemolytic anemia (AIHA)[J]. Blood, 2018, 132(S1): 3623.
|
| [43] |
Apellis Pharmaceuticals, Inc. Study to assess the safety, tolerability, efficacy and PK of APL-2 in patients with warm type autoimmune hemolytic anemia (wAIHA) or cold agglutinin disease (CAD)[EB/OL ]. (2024-12-12)[2025-01-20]. https://classic.clinicaltrials.gov/ct2/show/NCT03226678.
|
| [44] |
Berentsen S, Hill A, Hill Q A, et al. Novel insights into the treatment of complement-mediated hemolytic anemias[J]. Ther Adv Hematol, 2019, 10: 2040620719873321. DOI: 10.1177/2040620719873321
|
| [45] |
Tahhan F, Huynh B, Xu P. Novel monoclonal antibody therapy in a patient with treatment-refractory warm autoimmune hemolytic anemia[J]. Cureus, 2022, 14(6): e26051.
|
| [46] |
Teigler J, Low J, Rose S, et al. Evidence of classical complement pathway involvement in a subset of patients with warm autoimmune hemolytic anemia[J]. Blood, 2021, 138(S1): 2001.
|
| [47] |
Annexon, Inc. Safety, tolerability, pharmacokinetics and pharmacodynamics of anx005 in participants with warm autoimmune hemolytic anemia (wAIHA)[EB/OL ]. (2024-01-19)[2024-08-20]. https://clinicaltrials.gov/study/NCT04661033.
|
| [48] |
Newland A C, Sánchez-González B, Rejtö L, et al. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia[J]. Am J Hematol, 2020, 95(2): 178-187. DOI: 10.1002/ajh.25680
|
| [49] |
Ling L E, Roy S, Daly T, et al. M281: a therapeutic anti-FcRn blocking antibody for rapid clearance of IgG and IgG autoantibodies in immune cytopenias and other auto/allo-immune disease[J]. Blood, 2015, 126(23): 3472. DOI: 10.1182/blood.V126.23.3472.3472
|
| [50] |
Kuter D J, Agajanian R, Arnold D M, et al. Fostamatinib, a spleen tyrosine kinase inhibitor, for the treatment of warm antibody autoimmune hemolytic anemia: initial results of the multicenter, open-label extension period of the Soar phase 2 study[J]. Blood, 2018, 132(S1): 3612.
|
| [51] |
Kuter D J, Piatek C, Röth A, et al. Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD)[J]. Am J Hematol, 2024, 99(1): 79-87. DOI: 10.1002/ajh.27144
|
| [52] |
Liu X F, Zhou H, Hu Y, et al. Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study[J]. Lancet Haematol, 2023, 10(6): e406-e418. DOI: 10.1016/S2352-3026(23)00034-0
|
| [53] |
Yu Hu, Xiaofan Liu, Hu Zhou, et al. Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Haematol. 2024 Aug; 11(8): e567-e579.
|
| [54] |
Li H M, Ji J, Du Y L, et al. Sirolimus is effective for primary relapsed/refractory autoimmune cytopenia: a multicenter study[J]. Exp Hematol, 2020, 89: 87-95. DOI: 10.1016/j.exphem.2020.08.001
|
| [55] |
Zhang Z X, Hu Q L, Yang C, et al. Sirolimus is effective for primary refractory/relapsed warm autoimmune haemolytic anaemia/Evans syndrome: a retrospective single-center study[J]. Ann Med, 2023, 55(2): 2282180. DOI: 10.1080/07853890.2023.2282180
|
| [1] | TAN Meijuan, YANG Shijie, XU Xiequn. A Bibliometric Analysis of Medullary Thyroid Carcinoma From 2000 to 2022[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 133-142. DOI: 10.12290/xhyxzz.2024-0146 |
| [2] | ZHANG Ning, RUAN Gechong, JIAO Yang, LIU Xiaoqing, Jonathan Lio, KANG Lin. Research Hotspots and Trends of Growth Mindset in Medical Education: A Bibliometric Analysis[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2024-0796 |
| [3] | JIANG Wenli, HUANG Tian, WANG Furui, ZHOU Guangbo, ZHENG Ya, WANG Yuping, HU Zenan. A Bibliometric Analysis of the Relationship Between Oral Microbiome and Digestive System Diseases[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2024-0877 |
| [4] | ZHANG Ning, ZHANG Xiaochen, HE Mu, SUN Xiaohong, KANG Lin, QU Xuan, ZHU Minglei. A Bibliometric Analysis of the Global Research on Multimorbidity in Older Adults from 2000 to 2023[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 867-876. DOI: 10.12290/xhyxzz.2023-0516 |
| [5] | LIU Weikang, CHEN Yiran, YANG Yinmo. Perioperative Hot Issues and Management Strategies for Pancreatic Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 740-746. DOI: 10.12290/xhyxzz.2024-0407 |
| [6] | SHI Jiyuan, TIAN Jinhui, GAO Ya, XU Jian'guo, LI Zheng. A Bibliometric Analysis of the Global Research Output on Artificial Intelligence Clinical Research[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 871-879. DOI: 10.12290/xhyxzz.2021-0746 |
| [7] | ZHANG Shan, LIU Zhaorui, LIU Jie. Relationship Between SerpinB9 and Tumors and Research Progress of SerpinB9 in Skin Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 852-857. DOI: 10.12290/xhyxzz.2021-0805 |
| [8] | XU Haojie, WANG Lu, LIU Mingjuan, ZHAO Lidan. Analysis of Integrating Training in Scientific Research and Clinical Practice among Current Medical Postgraduates of Three Academic Systems[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(1): 66-73. DOI: 10.12290/xhyxzz.2021-0623 |
| [9] | Xiu-kai CHEN, Rong-li YANG. Septic Acute Kidney Injury: a Calm Thinking about the Hot Topics[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(6): 336-341. DOI: 10.3969/j.issn.1674-9081.2017.06.004 |
| 1. |
刘玉文，张丽梅，王永丽，徐小梅，母亚丹，杨志杰，杨树婷，罗凤云. 老年多学科团队服务对共病伴营养不良老年患者的疗效分析. 昆明医科大学学报. 2024(12): 81-87 .
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: